Implantable Infusion Pumps Market Key Opportunities and Forecast up to 2027
Implantable infusion pumps are used for long-term delivery of drugs in human patients. These have several advantages over conventional methods of drug administration. An implantable infusion device is used to provide access to deliver the needed drug to a specific body site. It can be programmed for continuous or variable rates of infusion. The pump is surgically placed in a subcutaneous pocket under the infraclavicular fossa or in the abdominal wall, and a catheter is threaded into the desired position.
Read Report Overview -
https://www.transparencymarketresearch.com/implantable-infusion-pumps-market.html
Implantable infusion pumps are easily removable, thereby providing a degree of therapeutic control for patients and providers. These devices can be used to deliver drugs to the intrathecal or subdural spinal spaces, numerous arteries leading directly to organs, cerebral ventricles, intravenous & subcutaneous systems, and the intraperitoneal space. These implantable infusion devices also have certain advantages over other types of liposomal or polymeric drug delivery systems.
Some implantable infusion pumps are designed only for stationary use at a patient’s bedside. Ambulatory implantable infusion pumps are designed to be portable or wearable. Health care facilities that use implantable infusion pumps should have policies and procedures in place to promote patient safety. Additional practices such as using "smart pump" technology could also be utilized to help reduce risks.
The FDA regulates implantable infusion pumps as combination products, which comprise two or more regulated components such as drugs, devices, and/or biological products, through the premarket approval process. Smart infusion pumps have several safety features that have made these the must-have technology in health care setting. The most popular feature of a smart pump is the drug library. The library is a database that holds drug dosing information, including dosing limits, infusion parameters, and drug specific advisories.
Request a PDF Sample on Implantable Infusion Pumps Market Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74071
Key Drivers of Global Implantable Infusion Pumps Market
Increase in incidence rate of cancer, diabetes, and obesity
According to the American Institute for Cancer Research, 12 types of cancer were identified in 175 countries and 6% of new cancer cases (nearly 800,000) in 2012 were caused by the combined effects of obesity or overweight and diabetes
Among individual risk factors, overweight was responsible for twice as many cancers (3.9%) as diabetes (2%)
Diabetes and high body-mass index (BMI), defined as a BMI greater than or equal to 25 kg/m2, are the leading causes of mortality and morbidity globally, and
prevalence of these disorders has increased substantially in the last four decades
According to a journal published by the National Center for Biotechnology Information, the global age-standardized adult prevalence of diabetes was reported to be 9% in men and 7.9% in women in 2014, affecting about 422 million adults.
Increase in adoption of implantable drug delivery techniques in surgeries
A promising alternative delivery method is the use of polymeric implantable devices to deliver drug compounds. Implantable drug delivery systems allow targeted and localized drug delivery and can achieve a therapeutic effect with lower concentrations of drug.
Medication implant technology can achieve longer-lasting, highly localized drug delivery with more accurate concentrations, and fewer side effects than any other method of administration
Implants have been proven to be beneficial in the treatment of inflammatory diseases
Product recalls and stringent regulations for new products act as major restraints
Product recalls by the Food and Drug Administration are likely to hamper the global implantable infusion pumps market
On August 09, 2017, Medtronic Synchromed II Model 8637 supplied in 20 mL and 40 mL reservoir size and a catheter offered by Medtronic Neuromodulation was recalled. The reason for the recall was that Medtronic implemented final design change intended to address the motor stall due to corrosion and recalled devices with the previous design that were not implanted.
North America to capture major share of global market
North America is projected to account for significant share of the global implantable infusion pumps market during the forecast period. The market in the region is anticipated to grow at a rapid pace in the near future, primarily due to technological advancements in medical devices and rise in demand for less invasive surgeries.
The implantable infusion pumps market in Asia Pacific is expected to expand at a rapid pace during the forecast period due to preference for minimally invasive procedures
Expanding Operations in Future? To Get the Perfect Launch Ask for a Custom Implantable Infusion Pumps Market Report.
Pre Book this Report -
https://www.transparencymarketresearch.com/checkout.php?rep_id=74071<ype=S
Key Players Operating in Global Market
The global implantable infusion pumps market is highly concentrated, due to strong presence of a few key players. A large number of manufacturers hold major shares of the market in their respective regions. Market players are adopting practices of appointing third-party distributors to strengthen their presence. This has led to surge in the number of distributors and suppliers in emerging markets. Leading players operating in the global implantable infusion pumps market are Medtronic, Medical Devices Business Services (Johnson's & Johnson), Primetech Corporation, Flowonix Medical, Inc., Tricumed Medizintechnik GmbH, Halyard Worldwide, Inc..